Notable Runner: 1.5 is Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Institutional Investor Sentiment

November 17, 2016 - By Pete Kolinski   ·   0 Comments

Notable Runner: 1.5 is Hemispherx Biopharma Inc's (NYSEMKT:HEB) Institutional Investor Sentiment

Sentiment for Hemispherx Biopharma Inc (NYSEMKT:HEB)

Hemispherx Biopharma Inc (NYSEMKT:HEB) institutional sentiment increased to 1.5 in Q2 2016. Its up 0.17, from 1.33 in 2016Q1. The ratio is more positive, as 9 funds started new and increased equity positions, while 6 sold and decreased their stakes in Hemispherx Biopharma Inc. The funds in our partner’s database reported: 14.64 million shares, down from 15.04 million shares in 2016Q1. Also, the number of funds holding Hemispherx Biopharma Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 3 Increased: 4 New Position: 5.

Hemispherx Biopharma, Inc. is a specialty pharmaceutical company. The company has a market cap of $20.48 million. The Firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. It currently has negative earnings. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

About 16,875 shares traded hands. Hemispherx BioPharma, Inc (NYSEMKT:HEB) has declined 47.62% since April 15, 2016 and is downtrending. It has underperformed by 52.24% the S&P500.

According to Zacks Investment Research, “Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.”

Bank Of America Corp De holds 0% of its portfolio in Hemispherx BioPharma, Inc for 214 shares. Bank Of New York Mellon Corp owns 66,806 shares or 0% of their US portfolio. Moreover, Blackrock Advisors Llc has 0% invested in the company for 68,726 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Blackrock Institutional Trust Company N.A., a California-based fund reported 5.76 million shares.#img1#

HEB Company Profile

Hemispherx Biopharma, Inc. (Hemispherx), incorporated on December 17, 1990, is a specialty pharmaceutical company. The Firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company’s products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). The Company’s Alferon Low Dose Oral (LDO) is a liquid natural interferon for oral administration.

Another recent and important Hemispherx BioPharma, Inc (NYSEMKT:HEB) news was published by Globenewswire.com which published an article titled: “Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split” on August 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Pete Kolinski


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>